VERA THERAPEUTICS INC
NASDAQ: VERA (Vera Therapeutics, Inc.)
Last update: 14 hours ago48.62
-2.02 (-3.99%)
| Previous Close | 50.64 |
| Open | 50.80 |
| Volume | 1,031,220 |
| Avg. Volume (3M) | 1,534,461 |
| Market Cap | 3,451,382,528 |
| Price / Book | 9.01 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.25 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eversept Partners, Lp | 30 Sep 2025 | 2,807,836 |
| Sofinnova Investments, Inc. | 30 Sep 2025 | 2,793,987 |
| Integral Health Asset Management, Llc | 30 Sep 2025 | 1,700,000 |
| Pictet Asset Management Holding Sa | 30 Sep 2025 | 1,439,121 |
| Tang Capital Management Llc | 30 Sep 2025 | 1,350,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 97.00 (Evercore ISI Group, 99.51%) | Buy |
| Median | 90.00 (85.11%) | |
| Low | 33.00 (Wedbush, -32.13%) | Hold |
| Average | 78.57 (61.60%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 45.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 19 Dec 2025 | 66.00 (35.75%) | Buy | 51.22 |
| 16 Oct 2025 | 48.00 (-1.28%) | Buy | 30.51 | |
| Goldman Sachs | 19 Dec 2025 | 95.00 (95.39%) | Buy | 51.22 |
| JP Morgan | 19 Dec 2025 | 96.00 (97.45%) | Buy | 51.22 |
| 07 Nov 2025 | 52.00 (6.95%) | Buy | 24.19 | |
| Wedbush | 11 Dec 2025 | 33.00 (-32.13%) | Hold | 46.02 |
| Evercore ISI Group | 08 Dec 2025 | 97.00 (99.51%) | Buy | 45.03 |
| TD Cowen | 05 Dec 2025 | 73.00 (50.14%) | Buy | 44.90 |
| HC Wainwright & Co. | 10 Nov 2025 | 90.00 (85.11%) | Buy | 27.75 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |